Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than placebo, according to a study published online April 23 in the New England Journal of Medicine.
Luke J. Laffin, M.D., from the Cleveland Clinic Foundation, and colleagues conducted a double-blind, randomized trial involving patients who were receiving two to five antihypertensive medications and had a blood pressure measurement of 140/90 mm Hg or higher obtained during an office visit. Participants underwent a standardized antihypertensive regimen for three weeks; those with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomly assigned to receive placebo, lorundrostat (50 mg daily; stable-dose group), or lorundrostat starting at 50 mg daily and increasing to 100 mg daily if systolic blood pressure was ≥130 mm Hg after four weeks (dose-adjustment group).
Two hundred eighty-five patients were randomly assigned: 94, 96, and 95 to the stable-dose group, dose-adjustment group, and placebo group, respectively. The researchers found that after 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was –15.4, –13.9, and –7.4 mm Hg in the stable-dose, dose-adjustment, and placebo groups, respectively. The placebo-adjusted change in blood pressure was –7.9 and –6.5 mm Hg in the stable-dose and dose-adjustment groups, respectively. In the combined lorundrostat groups, the placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 was –5.3 mm Hg.
"Aldosterone synthase inhibition with lorundrostat effectively lowered blood pressure in patients with uncontrolled and treatment-resistant hypertension," the authors write.
Several authors disclosed ties to biopharmaceutical, medical device, and medical technology companies, including Mineralys Therapeutics, which is developing lorundrostat and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Maternal Cardiometabolic Risk Factors Tied to Higher BP in Offspring
WEDNESDAY, May 14, 2025 -- Maternal cardiometabolic risk factors are significantly associated with higher blood pressure (BP) in childhood for their offspring, according to a...
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.